Literature DB >> 32816082

Plasma sphingolipids and risk of cardiovascular diseases: a large-scale lipidomic analysis.

Jowy Yi Hoong Seah1,2, Wee Siong Chew3, Federico Torta4,5, Chin Meng Khoo6, Markus R Wenk4,5,7, Deron R Herr3,8, Hyungwon Choi9,6,10, E Shyong Tai9,6,11, Rob M van Dam12,13,14.   

Abstract

INTRODUCTION: Sphingolipids are a diverse class of lipids with various roles in cell functions and subclasses such as ceramides have been associated with cardiovascular diseases (CVD) in previous studies.
OBJECTIVES: We aimed to measure molecularly-distinct sphingolipids via a large-scale lipidomic analysis and expand the literature to an Asian population.
METHODS: We performed a lipidomics evaluation of 79 molecularly distinct sphingolipids in the plasma of 2627 ethnically-Chinese Singaporeans.
RESULTS: During a mean follow-up of 12.9 years, we documented 152 cases of major CVD (non-fatal myocardial infarction, stroke and cardiovascular death). Total ceramide concentrations were not associated with CVD risk [hazard ratio (HR), 0.99; 95% CI 0.81-1.21], but higher circulating total monohexosylceramides (HR, 1.22; 95% CI 1.03, 1.45), total long-chain sphingolipids (C16-C18) (HR, 1.22; 95% CI 1.02, 1.45) and total 18:1 sphingolipids (HR, 1.21; 95% CI 1.01, 1.46) were associated with higher CVD risk after adjusting for conventional CVD risk factors.
CONCLUSIONS: Our results do not support the hypothesis that higher ceramide concentrations are linked to higher CVD risk, but suggest that other classes of sphingolipids may affect CVD risk.

Entities:  

Keywords:  Cardiovascular mortality; Ceramides; Cerebrosides; Gangliosides; Heart disease; Hexosylceramides; Lipidomics; Sphingomyelin

Mesh:

Substances:

Year:  2020        PMID: 32816082     DOI: 10.1007/s11306-020-01709-8

Source DB:  PubMed          Journal:  Metabolomics        ISSN: 1573-3882            Impact factor:   4.290


  6 in total

Review 1.  Lipid Metabolite Biomarkers in Cardiovascular Disease: Discovery and Biomechanism Translation from Human Studies.

Authors:  Peter McGranaghan; Jennifer A Kirwan; Mariel A Garcia-Rivera; Burkert Pieske; Frank Edelmann; Florian Blaschke; Sandeep Appunni; Anshul Saxena; Muni Rubens; Emir Veledar; Tobias Daniel Trippel
Journal:  Metabolites       Date:  2021-09-14

2.  Dietary Fat and Protein Intake in Relation to Plasma Sphingolipids as Determined by a Large-Scale Lipidomic Analysis.

Authors:  Jowy Yi Hoong Seah; Wee Siong Chew; Federico Torta; Chin Meng Khoo; Markus R Wenk; Deron R Herr; E Shyong Tai; Rob M van Dam
Journal:  Metabolites       Date:  2021-02-08

Review 3.  Integrating lipidomics and genomics: emerging tools to understand cardiovascular diseases.

Authors:  Rubina Tabassum; Samuli Ripatti
Journal:  Cell Mol Life Sci       Date:  2021-01-15       Impact factor: 9.261

4.  AdipoAtlas: A reference lipidome for human white adipose tissue.

Authors:  Mike Lange; Georgia Angelidou; Zhixu Ni; Angela Criscuolo; Jürgen Schiller; Matthias Blüher; Maria Fedorova
Journal:  Cell Rep Med       Date:  2021-09-22

Review 5.  Role of Ceramides in the Molecular Pathogenesis and Potential Therapeutic Strategies of Cardiometabolic Diseases: What we Know so Far.

Authors:  Youssef M Shalaby; Anas Al Aidaros; Anjana Valappil; Bassam R Ali; Nadia Akawi
Journal:  Front Cell Dev Biol       Date:  2022-01-19

6.  Serum Lipidome Signatures of Dogs with Different Endocrinopathies Associated with Hyperlipidemia.

Authors:  Nadja S Sieber-Ruckstuhl; Wai Kin Tham; Franziska Baumgartner; Jeremy John Selva; Markus R Wenk; Bo Burla; Felicitas S Boretti
Journal:  Metabolites       Date:  2022-03-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.